Annals of Vascular Surgery
Volume 23, Issue 2 , Pages 172-178 , March 2009

Inflammatory Profiling of Peripheral Arterial Disease

  • Ramakrishna P.C. Chaparala

      Affiliations

    • Leeds Vascular Institute, Leeds General Infirmary, Leeds, UK
    • Corresponding Author InformationCorrespondence to: Ramakrishna P. C. Chaparala, Leeds Vascular Institute, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK
    • ,
  • Nicolas M. Orsi

      Affiliations

    • Perinatal Research Group, YCR & Liz Dawn Pathology & Translational Sciences Centre, Leeds Institute of Molecular Medicine, St. James's University Hospital, Leeds, UK
    • ,
  • Nigel J. Lindsey

      Affiliations

    • Department of Biomedical Sciences, University of Bradford, Bradford, West Yorkshire, UK
    • ,
  • Raman S. Girn

      Affiliations

    • Leeds Vascular Institute, Leeds General Infirmary, Leeds, UK
    • ,
  • Shervanthi Homer-Vanniasinkam

      Affiliations

    • Leeds Vascular Institute, Leeds General Infirmary, Leeds, UK

References 

  1. Criqui MH, Fronek A, Barret-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71:510–515
  2. Dieter RS, Chu WW, Pacanowski JP, McBride PE, Tanke TE. The significance of lower extremity peripheral arterial disease. Clin Cardiol. 2002;25:3–10
  3. Leng GC, Papacosta O, Whincup P, et al. Femoral atherosclerosis in an older British population: prevalence and risk factors. Atherosclerosis. 2000;152:167–174
  4. Murabito JM, D'Agostino RB, Silbershatz H, Wison PWF. Intermittent claudication, a risk profile from the Framingham Heart Study. Circulation. 1997;96:44–49
  5. Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  6. Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation. 1993;88:837–845
  7. Dormandy J, Heeck L, Vig S. Predictors of early diseases in the lower limbs. Semin Vasc Surg. 1999;12:109–117
  8. Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GD, Fowkes FG. Plasma fibrinogen, hemostatic factors and prediction of peripheral arterial disease in the Edinburgh Artery Study. Blood Coagul. Fibrinolysis. 2000;11:43–50
  9. Ridker PM, Meir J, Stampfe N, Rifai N. Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481–2485
  10. Fiotti N, Giansante C, Ponte E, et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis. 1999;145:51–60
  11. Armitage JD, Lindsey NJ, Homer-Vanniasinkam S. The role of endothelial cell reactive antibodies in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2006;31:170–175
  12. Papa ND, Raschi E, Moroni G, et al. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus. 1999;8:423–429
  13. Shoenfeld Y, Sherer Y, George J, Harats D. Autoantibodies associated with atherosclerosis. Ann Med. 2000;32(Suppl. 1):37–40
  14. Signorelli SS, Mazzarino MC, Di Pino L, et al. High circulating levels of cytokines (IL-6 and TNF-alpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med. 2003;8:15–19
  15. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J Med. 2005;352:1685–1695
  16. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J. 1989;8:3773–3779
  17. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996;127:263–271
  18. Yazici ZA, Raschi E, Patel A, et al. Human monoclonal anti-endothelial cell IgG derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. Int Immunol. 2001;13:349–357
  19. von Aulock S, Schröder NW, Gueinzius K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis. 2003;188:938–943
  20. Neumann FJ, Waas W, Diehm C, et al. Activation and decreased deformability of neutrophils after intermittent claudication. Circulation. 1990;82:922–999
  21. Brevetti G, De Caterina M, Martone VD, et al. Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudication. Clin Hemorheol Microcirc. 2001;24:193–199
  22. Kirk G, Hickman P, McLaren M, Stonebridge PA, Belch JJ. Interleukin-8 (IL-8) may contribute to the activation of neutrophils in patients with peripheral arterial occlusive disease (PAOD). Eur J Vasc Endovasc Surg. 1999;18:434–438
  23. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease?. Immunol Today. 1995;16:27–33
  24. Yildirir A, Muderrisoglu H. Non lipid effects of statins. Curr Vasc Pharmacol. 2004;2:309–318
  25. Boisvert WA, Curtiss LK, Terkeltaub RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res. 2000;21:129–137
  26. DePalma RG, Hayes VW, Cafferata HT, et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res. 2003;111:215–221
  27. Bonecchi R, Facchetti F, Dusi S, et al. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol. 2000;164:3862–3869
  28. Folcik VA, Aamir R, Cathcart MK. Cytokine modulation of LDL oxidation by activated human monocytes. Arterioscler Thromb Vasc Biol. 1997;17:1954–1961
  29. Goebeler M, Schnarr B, Toksoy A, et al. Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology. 1997;91:450–457
  30. Cimminiello C, Arpaia G, Toschi V, et al. Plasma levels of tumour necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud phenomenon. Angiology. 1994;45:1015–1022
  31. Uyemura K, Demer LL, Castle SC, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest. 1996;97:2130–2138
  32. Brevetti G, Piscione F, Silvestro A, et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost. 2003;89:1058–1063
  33. Matsuura E, Kobayashi K, Kasahara J, et al. Anti-beta 2-glycoprotein I autoantibodies and atherosclerosis. Int Rev Immunol. 2002;21:51–66
  34. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23–27
  35. Phadke KV, Phillips RA, Clarke DT, Jones M, Naish P, Carson P. Anticardiolipin antibodies in ischaemic heart disease: marker or myth?. Br Heart J. 1993;69:391–394
  36. Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet. 1992;339:451–453
  37. George J, Harats D, Gilburd B, et al. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation. 2000;102:1822–1827
  38. Neumann FJ, Waas W, Diehm C, et al. Activation and decreased deformability of neutrophils after intermittent claudication. Circulation. 1990;82:922–929

PII: S0890-5096(08)00214-8

doi: 10.1016/j.avsg.2008.06.005

Annals of Vascular Surgery
Volume 23, Issue 2 , Pages 172-178 , March 2009

Article Tools

* Image Usage & Resolution